Workshop: Antiviral Drug Development for Human Papillomaviruses

Despite the availability of highly effective HPV prophylactic vaccines, there remains a large unmet need for HPV therapeutic drugs for individuals who are already infected with the virus.  Given the current and projected rate of vaccine uptake worldwide, this situation will likely remain for decades.

Co-organized by Dr. John Schiller from the National Cancer Institute and colleagues from the National Institute of Allergy and Infectious Diseases, both part of the National Institutes of Health, USA, the workshop consists of two half-day sessions on May 5th and May 6th.

May 5^th 11AM-3:30 PM ET (New York) / 4PM-8:30PM GMT (London)

May 6^th 11AM-4:00 PM ET (New York) / 4PM-9:00PM GMT (London)

The purpose of this workshop is to:

•  document unmet disease burdens
•  prioritize potential disease targets for treatment and outline potential clinical trial designs
• evaluate models for preclinical testing
• discuss current candidates in the pipeline
•  provide information on potential public and private resources that are available to academic investigators to advance the development of antivirals for HPV

Registrations are open until May 4th.